Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016;51(4):961-77.
doi: 10.3233/JAD-150980.

Unraveling Alzheimer's: Making Sense of the Relationship between Diabetes and Alzheimer's Disease1

Melissa A Schilling
Free PMC article
Review

Unraveling Alzheimer's: Making Sense of the Relationship between Diabetes and Alzheimer's Disease1

Melissa A Schilling. J Alzheimers Dis. .
Free PMC article
Favorites

Abstract

Numerous studies have documented a strong association between diabetes and Alzheimer's disease (AD). The nature of the relationship, however, has remained a puzzle, in part because of seemingly incongruent findings. For example, some studies have concluded that insulin deficiency is primarily at fault, suggesting that intranasal insulin or inhibiting the insulin-degrading enzyme (IDE) could be beneficial. Other research has concluded that hyperinsulinemia is to blame, which implies that intranasal insulin or the inhibition of IDE would exacerbate the disease. Such antithetical conclusions pose a serious obstacle to making progress on treatments. However, careful integration of multiple strands of research, with attention to the methods used in different studies, makes it possible to disentangle the research on AD. This integration suggests that there is an important relationship between insulin, IDE, and AD that yields multiple pathways to AD depending on the where deficiency or excess in the cycle occurs. I review evidence for each of these pathways here. The results suggest that avoiding excess insulin, and supporting robust IDE levels, could be important ways of preventing and lessening the impact of AD. I also describe what further tests need to be conducted to verify the arguments made in the paper, and their implications for treating AD.

Keywords: Alzheimer disease; amylin; amyloid beta-peptide; dementia; diabetes mellitus; insulin; insulysin; metalloproteases; neprilysin.

Figures

Fig.1
The insulin-protease-amyloid degradation pathway and its potential malfunctions.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by 8 articles

See all "Cited by" articles

References

    1. (2015) 2015 Alzheimer’s disease facts and figures. Alzheimers Dement 11, 332–384. - PubMed
    1. Hurd MD, Martorell P, Delavande A, Mullen KJ, Langa KM (2013) Monetary costs of dementia in the United States. N Engl J Med 368, 1326–1334. - PMC - PubMed
    1. Kavirajan H, Schneider LS (2007) Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: A meta-analysis of randomised controlled trials. Lancet Neurol 6, 782–792. - PubMed
    1. Korczyn AD (2012) Why have we failed to cure Alzheimer’s disease?. J Alzheimers Dis 29, 275–282. - PubMed
    1. Trinh NH, Hoblyn J, Mohanty SU, Yaffe K (2003) Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease - A meta-analysis. JAMA 289, 210–216. - PubMed

MeSH terms

Feedback